Femipil 0.03 mg+0.15 mg+75 mg (Tablet)

(21 white+7 brown) tablet: ৳ 24.50

Medicine Details

Category	Details
Generic	Ethinyl estradiol levonorgestrel ferrous fumarate
Company	Beximco pharmaceuticals ltd

Indications

Inhibit Ovulation
Inhibit sperm to enter into the uterus by condensing uterine mucus
Inhibit fertilized egg to accept by uterus by protecting the growth of membrane inside the uterus
Reduces the movement of sperm by minimizing normal movement of fallopian tube
Suitable for women aged between 15-69 years (except smoker and who use tobacco regularly)
Temporary contraceptive method for women
Anemia treatment due to excessive blood loss during menstruation
Management of irregular menstruation cycle
Suitable for breastfeeding mothers (if child age is more than 6 months)

Composition

Each White (Hormone) Tablet contains Ethinylestradiol USP 0.03 mg & Levonorgestrel USP 0.15 mg. Each Brown color (Iron) tablet contains Ferrous Fumarate BP 75 mg.

Pharmacology

Contains Levonorgestrel and Ethinyl Estradiol. Suppresses ovulation. May include cervical mucus changes inhibiting sperm penetration and endometrial changes reducing likelihood of implantation.

Dosage & Administration

Start taking tablet from the first day of menstruation. Take one tablet same time each day. Start with white tablet for 3 weeks, then brown tablet for 7 days. If menstruation starts while taking brown tablet, continue the medication.

Interaction

Enzyme inducers may decrease effectiveness. Avoid caffeine, dairy foods, phytic acid containing food while taking the drug.

Contraindications

Known hypersensitivity to any of the components of this product.

Side Effects

Headache
Nausea
Mood changes including depression
Vaginal infections
Irregular vaginal bleeding
Pain and discomfort
Liver tumors
Jaundice
High blood pressure
Gallbladder problem

Pregnancy & Lactation

Contraindicated in pregnancy
Discontinue if pregnancy occurs
Reduce milk production in breastfeeding females

Precautions & Warnings

Stop if a thrombotic disorder occurs
Stop at least 4 weeks before through 2 weeks after major surgery
Discontinue if jaundice occurs
Monitor blood pressure and stop if it rises significantly
Monitor prediabetic and diabetic women
Evaluate significant change in headaches and discontinue if indicated
Evaluate irregular bleeding or amenorrhea

Use in Special Populations

Safety and efficacy established in women of reproductive age. Efficacy expected to be the same in post-pubertal adolescents under the age of 18 years.

Overdose Effects

No reports of serious illness effects. Over dosage may cause withdrawal bleeding in females and nausea.

Therapeutic Class

Oral Contraceptive preparations

Storage Conditions

Store below 30°C, protected from light and moisture. Keep all medicines out of reach of children.